Tags

Type your tag names separated by a space and hit enter

Are the emerging SARS-COV-2 mutations friend or foe?
Immunol Lett. 2021 02; 230:63-64.IL

Authors+Show Affiliations

Internal Medicine, Silivri, Istanbul, Turkey. Electronic address: eroladnan@protonmail.com.

Pub Type(s)

Letter

Language

eng

PubMed ID

33400966

Citation

Erol, Adnan. "Are the Emerging SARS-COV-2 Mutations Friend or Foe?" Immunology Letters, vol. 230, 2021, pp. 63-64.
Erol A. Are the emerging SARS-COV-2 mutations friend or foe? Immunol Lett. 2021;230:63-64.
Erol, A. (2021). Are the emerging SARS-COV-2 mutations friend or foe? Immunology Letters, 230, 63-64. https://doi.org/10.1016/j.imlet.2020.12.014
Erol A. Are the Emerging SARS-COV-2 Mutations Friend or Foe. Immunol Lett. 2021;230:63-64. PubMed PMID: 33400966.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Are the emerging SARS-COV-2 mutations friend or foe? A1 - Erol,Adnan, Y1 - 2021/01/02/ PY - 2020/12/28/received PY - 2020/12/29/accepted PY - 2021/1/6/pubmed PY - 2021/1/30/medline PY - 2021/1/5/entrez SP - 63 EP - 64 JF - Immunology letters JO - Immunol Lett VL - 230 SN - 1879-0542 UR - https://www.unboundmedicine.com/medline/citation/33400966/Are_the_emerging_SARS_COV_2_mutations_friend_or_foe L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-2478(20)30442-9 DB - PRIME DP - Unbound Medicine ER -